MilliporeSigma
  • BDNF signaling in the VTA links the drug-dependent state to drug withdrawal aversions.

BDNF signaling in the VTA links the drug-dependent state to drug withdrawal aversions.

The Journal of neuroscience : the official journal of the Society for Neuroscience (2014-06-06)
Hector Vargas-Perez, Amine Bahi, Mary Rose Bufalino, Ryan Ting-A-Kee, Geith Maal-Bared, Jenny Lam, Ahmed Fahmy, Laura Clarke, Jennifer K Blanchard, Brett R Larsen, Scott Steffensen, Jean-Luc Dreyer, Derek van der Kooy
ABSTRACT

Drug administration to avoid unpleasant drug withdrawal symptoms has been hypothesized to be a crucial factor that leads to compulsive drug-taking behavior. However, the neural relationship between the aversive motivational state produced by drug withdrawal and the development of the drug-dependent state still remains elusive. It has been observed that chronic exposure to drugs of abuse increases brain-derived neurotrophic factor (BDNF) levels in ventral tegmental area (VTA) neurons. In particular, BDNF expression is dramatically increased during drug withdrawal, which would suggest a direct connection between the aversive state of withdrawal and BDNF-induced neuronal plasticity. Using lentivirus-mediated gene transfer to locally knock down the expression of the BDNF receptor tropomyosin-receptor-kinase type B in rats and mice, we observed that chronic opiate administration activates BDNF-related neuronal plasticity in the VTA that is necessary for both the establishment of an opiate-dependent state and aversive withdrawal motivation. Our findings highlight the importance of a bivalent, plastic mechanism that drives the negative reinforcement underlying addiction.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Lithium chloride, powder, ≥99.98% trace metals basis
Sigma-Aldrich
Lithium chloride, AnhydroBeads, −10 mesh, 99.998% trace metals basis
Supelco
Heroin, analytical standard, ≥98% (HPLC)
Supelco
Lidocaine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Lidocaine, European Pharmacopoeia (EP) Reference Standard
Lidocaine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
ProBDNF human, recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC)
Sigma-Aldrich
BDNF human, Carrier free, recombinant, expressed in E. coli, ≥95% (SDS-PAGE), suitable for cell culture
Sigma-Aldrich
Lithium chloride, ACS reagent, ≥99%
Sigma-Aldrich
Lithium chloride, puriss. p.a., anhydrous, ≥99.0% (AT)
USP
Lidocaine, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Lithium chloride, AnhydroBeads, −10 mesh, ≥99.9% trace metals basis
Sigma-Aldrich
Lithium chloride, ReagentPlus®, 99%
Sigma-Aldrich
Lithium chloride, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99%
Sigma-Aldrich
Lithium chloride, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, 99%
Sigma-Aldrich
Lithium chloride, BioXtra, ≥99.0% (titration)
Sigma-Aldrich
Lithium chloride, for molecular biology, ≥99%
Sigma-Aldrich
Lithium chloride, BioUltra, for molecular biology, anhydrous, ≥99.0% (AT)
Sigma-Aldrich
Lithium-7Li chloride, 99 atom % 7Li, 99% (CP)
Sigma-Aldrich
Brain-derived neurotrophic factor human, BDNF, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
Sigma-Aldrich
Lidocaine, powder
Sigma-Aldrich
Lidocaine, analytical standard
Supelco
Lidocaine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Morphine sulfate salt solution, 1.0 mg/mL in methanol, drug standard
Sigma-Aldrich
Muscimol hydrobromide, ≥98% (HPLC), solid
Sigma-Aldrich
Lithium chloride solution, 8 M, for molecular biology, ≥99%
Supelco
Lithium chloride solution, 1 M in ethanol
Supelco
Electrolyte solution, nonaqueous, 2 M LiCl in ethanol